Tulisokibart was linked to clinical, endoscopic and histologic remission in patients with ulcerative colitis following 12 ...
Average dietary fiber intake is lower among patients with active vs inactive inflammatory bowel disease, particularly among ...
Eilean Therapeutics LLC is a biopharmaceutical company focused on the discovery and development of best-in-class and first-in-class small-molecule therapies addressing genetic and signaling ...
SAN DIEGO & COPENHAGEN, Denmark--(BUSINESS WIRE)--AFYX Therapeutics (“AFYX”), a clinical-stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, announced results ...
The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...
The PROMETHEUS Monitr Crohn's Disease test can be used as an adjunct to endoscopy or by itself between endoscopies. A new noninvasive test to help measure and monitor mucosal healing status in Crohn’s ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Experts argued for the development of COVID-19 vaccines ...
Although anti-inflammatory treatments are quite effective at reducing symptoms in patients with Crohn's disease and ulcerative colitis, the mucosal lining of the intestine often remains ulcerated, and ...
Bacteriophages, viruses that infect bacteria, have been shown to preferentially bind to mucosal surfaces. This has been suggested to provide an extra level of immunity against bacterial infections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback